Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Investment Securities (2020 - 2025)

Insight Molecular Diagnostics' Gains from Investment Securities history spans 6 years, with the latest figure at $3.4 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $3.4 million; the TTM value through Sep 2025 reached $10.4 million, changed N/A, while the annual FY2024 figure was $1.0 million, 6228.63% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $3.4 million at Insight Molecular Diagnostics, up from $2.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $25.0 million in Q4 2021 and bottomed at -$18.3 million in Q1 2023.
  • The 5-year median for Gains from Investment Securities is $1.1 million (2021), against an average of $2.3 million.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 6135.29% in 2021 before it tumbled 21296.67% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $25.0 million in 2021, then plummeted by 30.97% to $17.3 million in 2022, then dropped by 1.14% to $17.1 million in 2023, then plummeted by 93.99% to $1.0 million in 2024, then surged by 229.14% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Gains from Investment Securities are $3.4 million (Q3 2025), $2.8 million (Q2 2025), and $879000.0 (Q1 2025).